LUNG · Pulmonx Corp
$2.42
+0.26 (+12.04%)
At close · Aug 14
Market Cap
$103.93M
Shares
42.95M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.42
Open$2.19
Day$2.16–2.49
52W close$1.17–2.60
Avg vol 30d652K
Short int1.1M · 2.5% float · 1.5d
Short vol46%
Last earningsJul 29, 2026
DataOct 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+48%
above
Price vs 50-day avg
+57%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
87%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+73%
trailing
6-month return
+64%
trailing
YTD return
+10%
this year
Relative strength
+50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +19 funds added
Insider flow
Distributing
Net -$144.0K over 90 days · 100% sells
Short interest
Rising
2.47% of float · ▲ +0.4% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
105 holders — near 3-yr low, contrarian setup
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
74%
expanding
EPS growth
+8%
Y/Y
Free cash flow
$-32.8M
Balance sheet
$32.8M
net cash
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Revenue
· full year 2026
$90M – $92M
Gross margin
· full year 2026
at least 76%
Total operating expenses
· full year 2026
$109M – $111M
Cash, cash equivalents, and marketable securities decrease
· full year 2026
at least $-23M
Prior guidance
period ended
· from the 8-K filed Nov 12, 2025
Total revenue
· full year 2025
$89M – $90M
Gross margin
· full year 2025
73%
Total operating expenses
· full year 2025
$125M – $126M
Guided vs delivered
· last 1 settled
Total revenue
full year 2025
guided $89M – $90M
$90.5M
Beat +1.1%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+48%
Bullish
Price vs 50-day avg
+57%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
87%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +19 funds added
Insider flow
Distributing
Net -$144.0K over 90 days · 100% sells
Short interest
Rising
2.47% of float · ▲ +0.4% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
105 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $2 · 87%
Range high $3
vs 200-day avg +48%
vs 50-day avg +57%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -13.66M | Six Months Ended June 30 | — |
| Adjusted EBITDA loss non-GAAP | -$5.1M | second quarter of 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LUNG
this stock
Pulmonx Corp
|
$103.93M | +9.5% | +8.0% | — | 2.5% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LUNG | +18.6% | +72.9% | +63.5% | +48.5% | +9.5% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +18.2% | +68.4% | +49.7% | +44.6% | -4.4% |